Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Alvotech (NASDAQ:ALVO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Lucid Diagnostics and Alvotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Alvotech | 1 | 2 | 5 | 0 | 2.50 |
Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 417.61%. Alvotech has a consensus target price of $8.50, indicating a potential upside of 43.58%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Lucid Diagnostics is more favorable than Alvotech.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $4.71 million | 34.91 | -$58.01 million | ($0.47) | -1.72 |
| Alvotech | $588.90 million | 3.03 | $27.92 million | ($0.61) | -9.70 |
Alvotech has higher revenue and earnings than Lucid Diagnostics. Alvotech is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
74.0% of Lucid Diagnostics shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Lucid Diagnostics and Alvotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -959.76% | N/A | -119.57% |
| Alvotech | -36.31% | -11.92% | -11.73% |
Volatility and Risk
Lucid Diagnostics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.
Summary
Lucid Diagnostics beats Alvotech on 9 of the 14 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
